The global Metabolomics market is anticipated to reach USD 2.1 billion in 2021 growing at a CAGR of 13.1% during the forecasting period, 2021-2028.
Metabolomics is used widely in various disease research areas. Mass spectrometry is one of the highly applicable technologies in various basic disciplines, identification of endogenous substances in living organisms and, providing technical support for the discovery. Furthermore, this technology plays a vital role in disease treatment (such as bladder cancer, cardiovascular disease, breast cancer, kidney cancer, gastric cancer, natural metabolic errors, nutrition, and toxicological effects) animal and plant research, drug characterization and agricultural research, and nutrition
Increasing R&D expenditure for pharmaceutical and biotechnology, and increasing demand for personalized medicine are some of the factors that have supported long-term expansion for the metabolomics industry.
The global metabolomics market is segmented into product, application, indication, end-user, and geography.
Product segment is segmented into GC, UPLC, CE, and Surface-based Mass Analysis
Indication segment is segmented into Cardiology, Oncology, and Inborn Errors
End-User segment is segmented into Academic Institute and CROs
Application segment is segmented into Biomarker Discovery, Drug Discovery, and Functional Genomics
Geographically, the global metabolomics market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions
Asia-Pacific region has recorded the highest growth rate in the overall global market during the forecast period 2021-2028.
Key players in the global metabolomics market are Waters Corporation, Agilent Technologies, Shimadzu Corporation, Thermo Fisher Scientific, Danaher Corporation, Bruker Corporation, PerkinElmer, Merck KGaA, GE Healthcare, Hitachi High-Technologies Corporation, Human Metabolome Technologies, Inc., LECO Corporation, Metabolon, Inc., Bio-Rad Laboratories, Scion Instruments, DANI Instruments S.p.A., GL Sciences, SRI Instruments, Kore Technology Ltd., and JASCO, Inc., among others
The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:
|
Report Feature |
Descriptions |
|---|---|
|
Market Revenue In 2021 |
USD 2.1 billion |
|
Growth Rate |
CAGR of 13.1% during the forecasting period, 2021-2028 |
|
Historical Data |
2018-2019 |
|
Forecast Years |
2021-2028 |
|
Base Year |
2020 |
|
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
|
Report Segmentation |
Product, Application, Indication, End-User, and Geography |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and the Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
Waters Corporation, Agilent Technologies, Shimadzu Corporation, Thermo Fisher Scientific, Danaher Corporation, Bruker Corporation, PerkinElmer, Merck KGaA, GE Healthcare, Hitachi High-Technologies Corporation, Human Metabolome Technologies, Inc., LECO Corporation, Metabolon, Inc., Bio-Rad Laboratories, Scion Instruments, DANI Instruments S.p.A., GL Sciences, SRI Instruments, Kore Technology Ltd., and JASCO, Inc., among others |
|
Available Customization |
In addition to the market data for the metabolomics market, Delvens. offers client-centric reports and customized according to the company’s specific demand and requirement. |
.png)
.png)
.png)
.png)
.png)
.png)